- Home
- Solutions
- By Diseases
- Congenital Ophthalmic Diseases
- Ocular Coloboma
The development of effective therapies for ocular coloboma requires a multifaceted approach, combining advanced diagnostic techniques with innovative therapeutic strategies. Protheragen is dedicated to pushing the boundaries of this field, offering a range of services that span from genetic analysis to preclinical research.
Ocular coloboma is a developmental disorder characterized by the presence of a hole in one of the eye's structures, including the iris, retina, choroid, or optic disc. This condition arises from the incomplete closure of the embryonic optic fissure, leading to a spectrum of clinical manifestations collectively known as the Microphthalmia, Anophthalmia, Coloboma (MAC) complex. The incidence of ocular coloboma is relatively low, affecting less than one in every 10,000 births, yet it accounts for a significant proportion of childhood blindness.
Fig.1 Transcriptome analysis of chicken optic fissure closure. (Trejo-Reveles V., et al., 2023)
Recent advancements in genetic research have emphasized the identification of novel candidate genes associated with ocular coloboma. For instance, integrative gene expression analyses across multiple vertebrate species have highlighted genes such as ALDH1A3, BMPR1B, EMX2, EPHB3, NID1, NTN1, PAX2, SMOC1, TENM3, and VAX1. These genes have been identified based on their enriched expression profiles during optic fissure development.
Next-generation sequencing (NGS) technologies have revolutionized the field, enabling the identification of causative variants in cases with MAC. For instance, targeted gene panels and whole genome sequencing have led to a genetic diagnosis rate of up to 33% in MAC cases, with panels now including over 86 different genes.
By leveraging our expertise in gene therapy and drug development, we aim to provide customized ocular coloboma diagnostics and therapeutic development services to meet the needs of global pharmaceutical companies.
Protheragen provides systematic target discovery to define causative genes, signaling nodes, and cellular processes driving optic fissure closure defects. Using multi-omic profiling (genomics, transcriptomics, epigenomics, proteomics) of patient-derived specimens and coloboma-relevant developmental datasets, we identify high-confidence therapeutic targets linked to fissure fusion, cell survival, and tissue integrity.
Our functional validation employs CRISPR-Cas9 and RNA interference in human pluripotent stem cell (hPSC)-derived ocular progenitors and organoids to model loss- and gain-of-function phenotypes. We quantify effects on optic fissure morphology, cell proliferation, apoptosis, and epithelial–mesenchymal transition using high-content imaging and single-cell transcriptomics. For genetic variants of uncertain significance, we perform in-silico structural prediction and functional complementation assays to establish pathogenicity. These services deliver a prioritized, mechanistically validated target list to guide subsequent drug discovery.
We specialize in constructing physiologically relevant preclinical models that recapitulate human ocular coloboma pathogenesis. Protheragen generates 3D human optic cup and retinal organoids from patient-specific induced pluripotent stem cells (iPSCs) carrying coloboma-associated mutations, enabling in-vitro modeling of tissue defects without animal bias. These organoids form layered retinal structures, optic fissure-like domains, and RPE monolayers that mimic key stages of human eye development.
We also provide genetic model characterization in zebrafish and mouse systems focused on developmental phenotypes, including morpholino-mediated gene knockdown, CRISPR mutant generation, and phenotypic scoring of fissure closure defects. Our team performs longitudinal imaging, histomorphometry, and gene expression profiling to confirm model fidelity. Clients receive fully characterized, ready-to-use models with standardized protocols for drug testing and mechanistic studies.
Protheragen operates automated screening platforms tailored to ocular coloboma therapy discovery. We design and execute phenotypic screens using organoid and zebrafish models to identify small molecules, gene therapies, and biologics that rescue fissure closure, reduce apoptosis, or restore retinal lamination.
Our high-content imaging pipelines quantify morphological rescue, fluorescence reporter activity, and marker expression at single-cell resolution. We offer custom library screening (focused on developmental pathways, anti-apoptotics, kinase inhibitors, and gene therapy enhancers) as well as dose–response profiling and structure–activity relationship (SAR) support. Hit compounds undergo counterscreening to eliminate ocular cytotoxicity and off-target developmental effects, yielding validated lead candidates for optimization.
We advance hit molecules toward preclinical candidates through iterative medicinal chemistry support, in-vitro pharmacology, and ocular pharmacokinetic (PK) assessment. Protheragen evaluates solubility, stability, cellular permeability, and metabolic stability in ocular cell lines and tissue explants. We establish in-vitro efficacy metrics including EC50, IC50, and functional rescue scores in coloboma organoids.
For gene therapies and oligonucleotides, we test vector performance, expression efficiency, and splicing correction in human ocular cells. Our bioanalytical services quantify drug levels in vitreous, retina, and RPE using LC-MS/MS and qPCR. These data enable rational formulation design for ocular delivery and support selection of candidates with favorable therapeutic indices.
Protheragen provides comprehensive in-vitro safety assessment to predict ocular tolerability and off-target developmental risks. We evaluate cytotoxicity, genotoxicity, and mitochondrial function in human retinal cells, RPE, and optic nerve progenitors. We assess irritancy, inflammatory potential, and effects on ocular developmental milestones using organoid and zebrafish models.
Our GLP-aligned toxicology profiling includes histopathological evaluation, oxidative stress measurement, and transcriptomic analysis of stress pathways. We deliver a complete safety profile to identify liabilities early and guide risk mitigation before advanced preclinical stages.
We support clinical readiness by discovering and validating predictive pharmacodynamic biomarkers for ocular coloboma therapies. Using transcriptomics, proteomics, and imaging biomarkers, we identify molecular signatures of optic fissure rescue, retinal maturation, and reduced tissue damage.
Protheragen develops quantitative PCR, digital PCR, and immunological assays to measure target engagement, gene expression, and protein levels in preclinical samples. We establish imaging biomarkers using optical coherence tomography (OCT) and fundus imaging in model systems to enable non-invasive longitudinal monitoring. These biomarkers support clinical trial planning and objective efficacy assessment in future human studies.
At Protheragen, our preclinical research services, including pharmacokinetic and toxicology studies, are dedicated to advancing the understanding of ocular coloboma and exploring novel therapeutic approaches. We employ state-of-the-art in vivo models and gene editing technology to investigate the roles of newly identified genes, thereby laying the groundwork for future therapeutics development. If you are interested in our services, please feel free to contact us.
Reference
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
As a research service provider, Protehragen offers a comprehensive range of cutting-edge services to advance the development of innovative therapies and unlock the future of rare eye disease therapeutics.
Congenital Ophthalmic Diseases
Hereditary Ophthalmic Diseases
Infectious Ophthalmic Diseases
Copyright © Protheragen. All rights reserved.